NKGen Biotech, Inc. Warrants
NKGen Biotech, Inc. operates as a clinical-stage biotechnology company that focuses on the development and commercialization of autologous, allogeneic, and CAR-NK natural killer cell therapies. Its lead products include SNK01, an autologous NK cell therapy candidate treatment for neurodegenerative diseases; and SNK02, an allogeneic NK cell therapy, which is in Phase 1 clinical trials for refracto… Read more
NKGen Biotech, Inc. Warrants (NKGNW) - Net Assets
Latest net assets as of June 2024: $-69.72 Million USD
Based on the latest financial reports, NKGen Biotech, Inc. Warrants (NKGNW) has net assets worth $-69.72 Million USD as of June 2024.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($15.65 Million) and total liabilities ($85.36 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-69.72 Million |
| % of Total Assets | -445.53% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
NKGen Biotech, Inc. Warrants - Net Assets Trend (2021–2023)
This chart illustrates how NKGen Biotech, Inc. Warrants's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for NKGen Biotech, Inc. Warrants (2021–2023)
The table below shows the annual net assets of NKGen Biotech, Inc. Warrants from 2021 to 2023.
| Year | Net Assets | Change |
|---|---|---|
| 2023-12-31 | $-58.69 Million | -3855.15% |
| 2022-12-31 | $1.56 Million | +104.11% |
| 2021-12-31 | $-38.05 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to NKGen Biotech, Inc. Warrants's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 10970800000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2023)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $2.00K | % |
| Other Components | $103.44 Million | % |
| Total Equity | $-58.69 Million | 100.00% |
NKGen Biotech, Inc. Warrants Competitors by Market Cap
The table below lists competitors of NKGen Biotech, Inc. Warrants ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
DELPHI AUTOMOTIVE
BE:D7A
|
$562.77K |
|
THE BITCOIN FUND UTS A
F:7T9
|
$562.81K |
|
Thor Mining PLC
PINK:THORF
|
$562.88K |
|
Multi Retail Group Ltd
TA:MRG
|
$562.89K |
|
Jade Leader Corp
PINK:MCKRF
|
$562.48K |
|
REALTY
MU:RY6
|
$562.32K |
|
ACME Lithium Inc
OTCQB:ACLHF
|
$561.74K |
|
AXIS SP GDR REG-S (UZC.SG)
STU:UZC
|
$561.63K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in NKGen Biotech, Inc. Warrants's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2022 to 2023, total equity changed from 1,563,000 to -58,693,000, a change of -60,256,000 (-3855.2%).
- Net loss of 82,954,000 reduced equity.
- New share issuances of 1,668,000 increased equity.
- Other factors increased equity by 21,030,000.
Equity Change Factors (2022 to 2023)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-82.95 Million | -141.34% |
| Share Issuances | $1.67 Million | +2.84% |
| Other Changes | $21.03 Million | +35.83% |
| Total Change | $- | -3855.15% |
Book Value vs Market Value Analysis
This analysis compares NKGen Biotech, Inc. Warrants's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | $-1.77 | $0.03 | x |
| 2022-12-31 | $0.25 | $0.03 | x |
| 2023-12-31 | $-3.80 | $0.03 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently NKGen Biotech, Inc. Warrants utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-570.57%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | 0.00% | -5461.27% | 0.02x | 0.00x | $-19.46 Million |
| 2022 | -1711.71% | -34745.45% | 0.00x | 10.45x | $-26.91 Million |
| 2023 | 0.00% | 0.00% | 0.00x | 0.00x | $-77.08 Million |
Industry Comparison
This section compares NKGen Biotech, Inc. Warrants's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $184,483,093
- Average return on equity (ROE) among peers: -41.08%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| NKGen Biotech, Inc. Warrants (NKGNW) | $-69.72 Million | 0.00% | N/A | $562.52K |
| Aadi Bioscience Inc (AADI) | $136.41 Million | -80.71% | 0.16x | $17.03 Million |
| America Great Health (AAGH) | $-48.07K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $408.66 Million | -216.05% | 5.93x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $59.51 Million |
| ABIVAX Société Anonyme (AAVXF) | $48.18 Million | -23.29% | 0.12x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $1.23 Billion | 12.85% | 0.25x | $740.10 Million |
| Abeona Therapeutics Inc (ABEO) | $102.55 Million | -82.14% | 0.47x | $210.89 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $-11.42 Million | 0.00% | 0.00x | $117.44 Million |
| Abpro Holdings, Inc. (ABP) | $-85.14 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $316.52 Million |